A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.

A cohort study found that nearly three fourths of infants received respiratory syncytial virus protection with either nirsevimab or through exposure to maternal RSVpreF in the 2023-2024 season.

Respiratory syncytial virus (RSV) infections can lead to serious complications, particularly in infants and older adults aged 75 years and above. Recent advancements in vaccine trials for older ...

Cases of flu and respiratory syncytial virus (RSV) are ticking up across the United States even as overall respiratory virus activity remains low.

New data for AREXVY, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease ...

An infection caused by the respiratory syncytial virus typically starts with cold-like symptoms such as nasal congestion, a runny nose, sore throat and fever. Photos: Shutterstock ...

GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons ...

Download this Respiratory Syncytial Virus Rsv Children Symptoms Infographic Doodle Vector Flat Cartoon Set Icon For Information Flyers Posters vector illustration now. And search more of iStock's ...

Impact of respiratory syncytial virus infection among patients with hematological cancer in the era of post-coronavirus pandemic.. If you have the appropriate software installed, you can download ...

Respiratory syncytial virus (RSV) is a leading cause of severe illness in infants, with no effective treatment. Results of a phase 2 trial suggested that ziresovir may have efficacy in the treatmen ...

Learn about Respiratory Syncytial Virus (RSV), its symptoms, treatment, and prevention. Get expert advice on how to protect vulnerable populations from this viral infection.